CAJ | 학술논문

目的：探讨瑞舒伐他汀联合氨氯地平对造影剂肾病是否具有保护作用。方法将142例患者随机被分为治疗组和对照组。2组在均进行水化基础上，分别于应用造影剂前7d和后3d口服安慰剂或氨氯地平及瑞舒伐他汀，比较2组患者造影后24 h、48 h及5 d时尿素氮、肌酐、肌酐清除率和尿β2微球蛋白、尿NAGL以及造影剂肾病发生率等指标。结果无论对照组还是治疗组，应用造影剂对患者肾功能均有明显影响（ P＜0．05）。应用造影剂后24 h治疗组尿β2微球蛋白和尿NGAL数值明显低于对照组（P＜0．05），其余指标无显著性差异。应用造影剂后48 h治疗组尿素氮、肌酐、肌酐清除率和尿β2微球蛋白、尿NAGL均显著优于对照组（P＜0．05）；应用造影剂后5 d治疗组和对照组比较，各指标差异仍有显著性（P＜0．05）。治疗组造影剂肾病发生率明显低于对照组（P＜0．05）。结论苯磺酸氨氯地平联合瑞舒伐他汀对造影剂肾病具有一定的预防及保护作用。
목적：탐토서서벌타정연합안록지평대조영제신병시부구유보호작용。방법장142례환자수궤피분위치료조화대조조。2조재균진행수화기출상，분별우응용조영제전7d화후3d구복안위제혹안록지평급서서벌타정，비교2조환자조영후24 h、48 h급5 d시뇨소담、기항、기항청제솔화뇨β2미구단백、뇨NAGL이급조영제신병발생솔등지표。결과무론대조조환시치료조，응용조영제대환자신공능균유명현영향（ P＜0．05）。응용조영제후24 h치료조뇨β2미구단백화뇨NGAL수치명현저우대조조（P＜0．05），기여지표무현저성차이。응용조영제후48 h치료조뇨소담、기항、기항청제솔화뇨β2미구단백、뇨NAGL균현저우우대조조（P＜0．05）；응용조영제후5 d치료조화대조조비교，각지표차이잉유현저성（P＜0．05）。치료조조영제신병발생솔명현저우대조조（P＜0．05）。결론분광산안록지평연합서서벌타정대조영제신병구유일정적예방급보호작용。
Objective To investigate the protective effect of rosuvastatin combined with amlodipine on contrast-induced nephropathy.Methods 142 cases were randomly divided into a treatment and a control group.Both groups took amlodipine and placebo or rosuvastatin orally,based on hydration,7 days before and 3 days after the application of the contrast agent.24h, 48h and 5d after the radiography,indicators of urea nitrogen,creatinine,creatinine clearance and urinary β2-microglobulin,u-rine NAGL and incidence of contrast-induced nephropathy were compared between the two groups.Results For both groups, renal function was significantly affected by the the application of contrast agents(P<0.05).24h after the application, urinaryβ2-microglobulin and urinary NGAL values of the treatment group were significantly lower than those of the control group( P<0.05),while the other indicators showed no significant difference.48h after the application,the indicators of urea nitrogen,cre-atinine,creatinine clearance and urinaryβ2-microglobulin, urine NAGL were significantly superior to the control group ( P<0.05).5d after the application, the indicators were still significantly different between the two groups(P<0.05).The inci-dence of contrast-induced nephropathy of the treatment group was significantly lower than the control group(P<0.05).Con-clusion Amlodipine combined with rosuvastatin has certain preventive and protective effect on contrast-induced nephropathy.